Anticoagulant News and Research

RSS

Newer anticoagulant medication may increase risk of GI bleeding in older patients

In a study released online in April in the BMJ, a team of researchers from Mayo Clinic, and other collaborators, showed that for older patients, particularly individuals greater than 75 years of age, the risk of gastrointestinal (GI) bleeding is 3 to 5 times higher when taking newer anticoagulant medications dabigatran or rivaroxaban compared to when using warfarin.

30 May 2015

Janssen, Bayer HealthCare initiate CALLISTO program to study rivaroxaban in patients with active cancer

Janssen Pharmaceuticals, Inc. and its development partner, Bayer HealthCare, today announced the initiation of CALLISTO, a new comprehensive clinical research program for their novel oral anticoagulant, rivaroxaban, in patients with active cancer. The studies are evaluating the medicine for the prevention and treatment of life-threatening blood clots in patients with a wide range of cancer types.

28 May 2015

COPD associated with increased mortality in patients with atrial fibrillation, but not stroke

Chronic obstructive pulmonary disease, or COPD, is associated with increased risk of dying from a cardiovascular disease such as heart failure or a heart attack, as well as diseases not associated with the heart. However, COPD is not by itself associated with increased likelihood of having a stroke or a systemic embolism, according to a new research study.

21 May 2015

Blood-thinning treatment safe for patients with brain metastases

Cancer patients with brain metastases who develop blood clots may safely receive blood thinners without increased risk of dangerous bleeding, according to a study, published online today in Blood, the Journal of the American Society of Hematology.

19 May 2015

Resverlogix, Hepalink announce equity investment and license agreement for RVX-208

Resverlogix Corp. today announced that it has entered into a Framework Agreement which sets forth the principal business terms for an equity investment and a license of RVX-208, for all indications, to Shenzhen Hepalink Pharmaceutical Co., Ltd. for China, Hong Kong, Taiwan and Macau (the "Territories").

27 Apr 2015

Ibrutinib (IMBRUVICA) may be effective for pancreatic ductal adenocarcinoma

Ibrutinib (IMBRUVICA) data presented yesterday by Pharmacyclics, Inc. at the American Association for Cancer Research Annual Meeting suggest that ibrutinib may be an effective therapeutic option for pancreatic ductal adenocarcinoma (PDAC), as shown in both a transgenic mouse model and an in-vivo model of patient-derived xenograft (PDX) mice (grafts of tissue taken from a pancreatic cancer patient and grafted into a mouse).

20 Apr 2015

Study looks at dabigatran adherence across Veterans Health Administration sites

Among patients with atrial fibrillation who filled prescriptions for the anticoagulant dabigatran at Veterans Health Administration sites, there was variability in patient medication adherence across sites, with appropriate patient selection and pharmacist-led monitoring associated with greater adherence to the medication, according to a study in the April 14 issue of JAMA.

16 Apr 2015

Pharmacyclics announces positive results from IMBRUVICA Phase II study in WM patients

Pharmacyclics, Inc. today announced longer-term data from a Phase II investigator-initiated study showing Waldenstrom's macroglobulinemia (WM) patients treated with IMBRUVICA (ibrutinib) experienced sustained disease control with an overall response rate (ORR) of 91% after a median of 19.1 months of treatment and a 2-year overall survival (OS) rate of 95%.

9 Apr 2015

Northwestern University researchers find safer way to improve surgery outcomes

A Northwestern University research team potentially has found a safer way to keep blood vessels healthy during and after surgery.

7 Apr 2015

New article highlights need for optimization of warfarin therapy

Warfarin can be a challenging drug to manage. Long-term anticoagulation is recommended for patients with atrial fibrillation at risk of stroke, and for those with recurrent venous thrombosis or prosthetic heart valves.

1 Apr 2015

Boston Scientific announces successful implantations of WATCHMAN Device in three US patients

This week, three patients in the United States received the first implants of the Boston Scientific Corporation WATCHMAN™ Left Atrial Appendage Closure (LAAC) Device.

25 Mar 2015

New study pinpoints major increase in subdural hematoma surgery by 2030

By 2030, chronic subdural hemorrhage (SDH) will be the most common adult brain condition requiring neurosurgical intervention in the U.S., according to a new study conducted by researchers at NYU Langone Medical Center.

23 Mar 2015

Anticoagulant drug bivalirudin shows mixed results in MATRIX trial

Patients with acute coronary syndrome undergoing angioplasty who received the anticoagulant drug bivalirudin did not show significant improvements in either of two co-primary endpoints--a composite of rate of death, heart attack or stroke at 30 days, or a composite of those events plus major bleeding--as compared to patients receiving standard anticoagulation therapy, according to a study presented at the American College of Cardiology's 64th Annual Scientific Session.

23 Mar 2015

Using arm as access point for catheter-based heart procedures lowers risk of major bleeding, death

Patients with acute coronary syndrome undergoing coronary angiogram, a procedure used to assess blockages in the heart's arteries, had a significantly lower risk of major bleeding and death if their interventional cardiologist accessed the heart through an artery in the arm rather than the groin, according to research presented at the American College of Cardiology's 64th Annual Scientific Session.

23 Mar 2015

New anti-clotting therapy no better than established anticoagulants

A novel therapy that would allow doctors to turn the body's blood-clotting ability off and on in a more controlled way was about as effective as established anticoagulants in patients undergoing angioplasty but was associated with higher rates of moderate to severe bleeding, according to an analysis of data from a terminated Phase III trial presented at the American College of Cardiology's 64th Annual Scientific Session.

20 Mar 2015

New pre-clinical, clinical data for IMBRUVICA to be highlighted at AACR Annual Meeting

Pharmacyclics, Inc. today announced that new pre-clinical and clinical data for ibrutinib (IMBRUVICA) will be highlighted at the 2015 American Association for Cancer Research Annual Meeting to be held April 18 – 22, 2015, in Philadelphia, PA.

19 Mar 2015

Janssen announces acquisition of XO1

Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today that it has acquired XO1 Limited, a privately held asset-centric virtual biopharmaceutical company founded to develop the anti-thrombin antibody ichorcumab.

19 Mar 2015

Selten Pharma's SPI-026 granted FDA Orphan Drug Designation for treatment of PAH

Selten Pharma, Inc., a privatively held biopharmaceutical company focused on the development and commercialization of therapies for the treatment of rare diseases, announced today that its lead compound tacrolimus (SPI-026) has been granted Orphan Drug Designation by the U.S. Food & Drug Administration for the treatment of pulmonary arterial hypertension (PAH).

18 Mar 2015

New ASH report outlines several models for 'systems-based clinical hematologist'

A report released today from the American Society of Hematology in its journal, Blood, presents an innovative, sustainable new role for hematologists, particularly those specializing in non-malignant blood diseases, for today’s rapidly changing U.S. health-care system.

9 Mar 2015

New blood thinner reduces stroke risk in patients with atrial fibrillation

Patients with high-risk atrial fibrillation, or AFib, often require one drug to regulate heart rhythm and a second drug to thin their blood and reduce the risk of stroke.

9 Mar 2015

Anticoagulant News and Research

Newer anticoagulant medication may increase risk of GI bleeding in older patients

Janssen, Bayer HealthCare initiate CALLISTO program to study rivaroxaban in patients with active cancer

COPD associated with increased mortality in patients with atrial fibrillation, but not stroke

Blood-thinning treatment safe for patients with brain metastases

Resverlogix, Hepalink announce equity investment and license agreement for RVX-208

Ibrutinib (IMBRUVICA) may be effective for pancreatic ductal adenocarcinoma

Study looks at dabigatran adherence across Veterans Health Administration sites

Pharmacyclics announces positive results from IMBRUVICA Phase II study in WM patients

Northwestern University researchers find safer way to improve surgery outcomes

New article highlights need for optimization of warfarin therapy

Boston Scientific announces successful implantations of WATCHMAN Device in three US patients

New study pinpoints major increase in subdural hematoma surgery by 2030

Anticoagulant drug bivalirudin shows mixed results in MATRIX trial

Using arm as access point for catheter-based heart procedures lowers risk of major bleeding, death

New anti-clotting therapy no better than established anticoagulants

New pre-clinical, clinical data for IMBRUVICA to be highlighted at AACR Annual Meeting

Janssen announces acquisition of XO1

Selten Pharma's SPI-026 granted FDA Orphan Drug Designation for treatment of PAH

New ASH report outlines several models for 'systems-based clinical hematologist'

New blood thinner reduces stroke risk in patients with atrial fibrillation

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News